A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)
Rekruitment:
Rekruitment abgeschlossen*
Indikation:
Multiples Myelom (MM)
Altersgruppe:
alle Altersgruppen
* Rekruitmentstatus einzelner österreichischer oder deutscher Zentren kann vom allgemeinen Status abweichen